# A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

> **NCT02997202** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 356 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** gilteritinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02997202
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2023-01-07
- **Final completion:** 2023-05-09
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997202, "A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02997202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*